Abiopharma

New Form SCHEDULE 13G/A - Arcturus Therapeutics Holdings Inc. Filed: 2026-01-08 AccNo: 0001623632-26-000033 Size: 46 KB

(99% Neutral) Coya Therapeutics, Inc. (COYA) Announces Clinical Development Update

ProQR Therapeutics (PRQR) Files Form 6-K

ProQR Press Release: ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

(100% Positive) COLLEGIUM PHARMACEUTICAL, INC. (COLL) Announces Business Combination

(80% Positive) Century Therapeutics, Inc. (IPSC) Provides Update on program for Type 1 Diabetes PHILADELPHIA

(90% Positive) XENCOR, INC. (XNCR) Announces Enrollment Update for data Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(85% Positive) BONE BIOLOGICS CORPORATION (BBLGW) Announces Enrollment Update for products Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Guardant Health, Inc. - Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

(99% Neutral) Spruce Biosciences, Inc. (SPRB) Announces Regulatory Update

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

(80% Positive) Personalis, Inc. (PSNL) Provides Update on results for breast cancer surveillance

EPAM Systems, Inc. - EPAM and Cursor Announce Strategic Partnership to Build and Scale AI-Native Teams for Global Enterprises

MannKind Provides Business Updates and 2026 Growth Drivers

CorMedix Therapeutics Announces Leadership and Board Updates